KFM Tablet contains a combination of Flupenthixol (0.5 mg) and Melitracen (10 mg), formulated to provide therapeutic benefits in the management of depressive and anxiety disorders. Flupenthixol is a typical antipsychotic agent with anxiolytic and antidepressant properties, primarily acting as a dopamine receptor antagonist, which helps in modulating mood and behavior. Melitracen, a tricyclic antidepressant, enhances the levels of neurotransmitters such as serotonin and norepinephrine in the central nervous system, contributing to improved mood and reduced anxiety symptoms. The synergistic effect of these two active ingredients makes KFM Tablet effective in treating conditions such as depression with associated anxiety, psychosomatic disorders, and other mood disturbances. It is generally prescribed when monotherapy with standard antidepressants is insufficient or when rapid symptom relief is desired. KFM Tablet should be used under medical supervision, with careful consideration of contraindications such as hypersensitivity to its components, severe cardiovascular disorders, and concurrent use of monoamine oxidase inhibitors (MAOIs). Common side effects may include dry mouth, dizziness, gastrointestinal discomfort, and sedation. Dose adjustments and monitoring are recommended to optimize therapeutic outcomes and minimize adverse effects.